版本:
中国

BRIEF-Crispr, Intellia, Caribou Biosciences, ERS Genomics announce appeal of CRISPR/CAS9 U.S. patent board decision

April 13 Crispr Therapeutics Ag

* Crispr Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics announce appeal of CRISPR/CAS9 U.S. patent board decision

* Crispr Therapeutics AG - appeal to U.S. Court of Appeals for federal circuit seeks review and reversal of patent trial

* Crispr Therapeutics AG - appeals board's decision to terminate CRISPR/CAS9 interference

* Crispr Therapeutics AG - companies and their licensors plan to pursue additional patents in U.S. and worldwide covering CRISPR/CAS9 technology Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐